Can You Donate Plasma If You’ve Had Cancer?

Whether you can donate plasma after a cancer diagnosis depends on what type of cancer you had, how long ago you finished treatment, and which donation center you walk into. In the United States, many former cancer patients are eligible to donate plasma and whole blood after a waiting period, but the rules are not uniform across cancer types or across countries. A 2023 survey of blood collection centers found that roughly three-quarters accepted donors with a history of solid tumors like carcinomas or sarcomas after treatment was complete, while about the same fraction permanently turned away anyone with a history of leukemia or lymphoma.¹ The distinction is not arbitrary, but the science behind it is less clear-cut than most people assume.

How the Rules Break Down by Cancer Type

Blood collection organizations generally sort former cancer patients into a few buckets. If you had a solid tumor, meaning cancers of the breast, colon, prostate, skin (other than melanoma in some cases), kidney, thyroid, or similar organs, most U.S. centers will consider you eligible once treatment is finished and your doctor considers you cancer-free. The American Red Cross, for example, allows donors who have had most solid tumors to give blood and plasma after successful treatment, though specific waiting periods and documentation requirements vary.

Blood cancers are treated very differently. A survey of 37 blood collection centers found that donors with a history of leukemia or lymphoma were permanently deferred at about three-quarters of responding centers, and those with myelodysplastic or myeloproliferative syndromes were permanently excluded at an even higher rate.¹ The reasoning is that these cancers originate in the blood-forming system itself, which makes the donated product a more direct concern, even if the donor has been in remission for years.

Some situations fall into gray areas. Prostate cancer patients on active surveillance, meaning they have a known cancer but are not receiving treatment because it is slow-growing, faced inconsistent deferrals across different centers in the same survey. Low-grade skin cancers like basal cell carcinoma are often not considered disqualifying at all, since they rarely spread beyond the skin. The upshot is that you should not assume a blanket “yes” or “no” based on a cancer diagnosis alone. The specific type and your treatment status matter enormously.

Why Blood Cancers Are Treated Differently

The permanent deferral for blood cancers reflects a basic concern about where the disease lives. Leukemia and lymphoma involve abnormal white blood cells circulating in the bloodstream, residing in bone marrow, and infiltrating lymph nodes. Even after successful treatment and years of remission, the worry is that residual abnormal cells could be present in donated blood or plasma at levels too low to detect with standard screening. Solid tumors, by contrast, arise in a specific organ. While cancer cells from solid tumors can occasionally enter the bloodstream, they are far less likely to survive in plasma products after the tumor itself has been removed or destroyed.

This distinction is partly rooted in biology and partly in caution. The same survey that documented these policies also noted that a thorough review of the medical literature found no evidence that cancer has ever been transmitted through a blood transfusion.¹ So the permanent deferral for blood cancers is a precautionary policy, not one supported by documented cases of harm. That does not necessarily make it wrong, but it does mean the rules are more conservative than the available evidence strictly requires.

What the Evidence Actually Shows About Cancer Transmission Through Blood

The strongest evidence on this question comes from a large study using the Scandinavian Donations and Transfusions database, which tracked over 350,000 transfusion recipients. Researchers identified about 12,000 recipients who had received blood from donors who were later diagnosed with cancer within five years of donating. These “precancerous” donors had undetected cancer, or cancer developing in their bodies, at the time they gave blood. If cancer could be transmitted through blood products, this would be the population most likely to show it.

The result was unambiguous: recipients of blood from precancerous donors had no increased risk of cancer compared to recipients of blood from donors who remained cancer-free. The adjusted relative risk was 1.00, with a confidence interval that ruled out any meaningful increase.² This held true across different cancer sites, meaning it was not just an average that hid a spike in one particular cancer type.

A broader literature review reached the same conclusion: despite millions of blood transfusions performed since blood banking began, there are no convincing reports of cancer being transmitted from donor to recipient through blood products.³ This is a striking finding given how many transfusions occur globally each year and how many donors have had undetected cancer at the time of donation. It suggests that even when cancer cells are present in donated blood, the recipient’s immune system eliminates them before they can establish a new tumor.

Why Cancer Cells in Blood Do Not Seem to Take Hold

The idea that cancer might spread through blood transfusion is not unreasonable on its face. Tumor cells do shed into the bloodstream; this is how metastasis works within a single person’s body. Researchers have explored whether circulating tumor cells in donated blood could pose a risk to recipients.⁴ But several factors work against transmission.

First, the number of circulating tumor cells in a person’s blood is extremely small, often just a handful per milliliter even in patients with active metastatic disease. In someone whose cancer is localized or in remission, the count is usually zero or near zero. Second, circulating tumor DNA, the fragments of genetic material shed by tumors, clears from the bloodstream remarkably fast, with a half-life as short as 16 minutes and rarely longer than about two and a half hours.⁵ This means that even the molecular remnants of a tumor vanish from circulation quickly. Third, a recipient’s immune system is remarkably good at recognizing and destroying foreign cells. Cancer cells that metastasize within a single body have already evolved to evade that person’s specific immune defenses. Foreign cancer cells from a donor have no such advantage, and the recipient’s immune system treats them much like any other foreign tissue.

Organ transplantation tells a revealing parallel story. There are rare documented cases of cancer transmission through organ transplants, but these occur specifically because transplant recipients take immunosuppressive drugs that disable the very immune surveillance that would normally destroy foreign cancer cells. Blood and plasma recipients are not immunosuppressed in the same way, which is likely why transfusion-transmitted cancer has never been convincingly documented.

How Rules Vary Around the World

If the evidence is this reassuring, you might expect uniform eligibility rules. In reality, policies differ dramatically between countries and sometimes between centers within the same country. A review of donor selection criteria in North America and Europe found wide disparities in how different blood services approach the same risks.⁶

The United States and Australia have historically been more permissive, allowing many cancer survivors to donate after treatment and a waiting period. Most other countries, including many in Europe, have traditionally imposed permanent deferrals for any history of cancer, regardless of type or how long ago it occurred.³ These permanent bans predate the large-scale studies that found no evidence of transmission risk, and they reflect an era when the precautionary principle was applied broadly in blood banking.

Some countries have begun updating their policies in light of newer evidence, but change is slow. Blood safety regulations are inherently conservative because the consequences of getting it wrong, even theoretically, are severe. When the existing policy has not caused a known shortage crisis, regulators often see little reason to relax it. This means that if you are a cancer survivor living in or traveling through different countries, your eligibility to donate plasma could change simply by crossing a border.

What Happens When You Show Up to Donate

If you have had cancer and want to donate plasma, the process starts with a health screening questionnaire that every donor completes. You will be asked directly about any history of cancer, what type it was, when you were diagnosed, and whether you have completed treatment. In most U.S. centers, your answers will be evaluated against the center’s specific guidelines, and you may be asked for documentation from your oncologist confirming that treatment is complete and that you are considered disease-free.

Some people are surprised to learn that the screening is largely self-reported. Blood and plasma donation centers do not run cancer-detection tests on donors. They rely on the donor’s honest disclosure, supplemented by basic health checks like vital signs, hemoglobin levels, and protein levels. This is true for all donors, not just those with a cancer history. The screening is designed to catch obvious health concerns, not to diagnose conditions the donor does not know about.

For plasma donation specifically, the center will also check your total serum protein level, since plasma donation removes proteins from your body that need to be replenished between donations. A study tracking donors over three years of intensive plasmapheresis found that while donors started with somewhat lower baseline protein and antibody levels compared to non-donors, continued regular donation did not further deplete these levels over time.⁷ For cancer survivors, this is relevant because some treatments, particularly certain chemotherapies and immunotherapies, can affect protein levels and immune function. If your protein or antibody levels have not recovered from treatment, you may be temporarily deferred even if your cancer history would otherwise be accepted.

Physical Considerations for Cancer Survivors

Eligibility is one question; whether donation is a good idea for your body is another. Cancer treatment takes a measurable toll on the body’s reserves. Chemotherapy can suppress bone marrow function for months after the last dose, reducing your red blood cell counts, white blood cell counts, and platelet counts. Radiation therapy, depending on where it was targeted, can have similar effects. Even surgery, if it was major, requires recovery time before your body can comfortably spare the volume of plasma removed during a donation.

Plasma donation is generally easier on the body than whole blood donation because the red blood cells are returned to you during the process. But it still removes a significant volume of fluid along with proteins, antibodies, and clotting factors. For someone whose immune system is still rebuilding after cancer treatment, the temporary dip in circulating antibodies after a plasma donation could be worth discussing with your oncologist. The same long-term safety study that showed intensive plasma donation did not progressively deplete protein levels also noted that some donors did experience temporary drops below acceptable thresholds, requiring them to take breaks.⁷

Most centers require that you be fully off cancer treatment, including hormone therapies like tamoxifen or aromatase inhibitors that some breast cancer survivors take for years. If you are still taking any medication related to your cancer, ask about it explicitly when you call the center. Maintenance medications that are not technically “treatment” but are cancer-related can create confusion during screening.

Common Misconceptions Worth Clearing Up

One persistent belief is that donating blood or plasma somehow “screens” you for cancer, because the blood is tested. This is not true. Donated blood and plasma are tested for infectious diseases like HIV, hepatitis B and C, syphilis, and a few others. Cancer is not among them. There is no routine test applied to donated blood that would detect cancer in the donor.

Another misconception is that cancer survivors are rejected from donation to protect the recipient from catching cancer. While recipient safety is the historical justification for deferral policies, the evidence strongly suggests this is not a real risk. The Scandinavian study’s finding of zero excess cancer risk among recipients of blood from donors who already had developing cancers is about as close to a definitive answer as epidemiology can provide.⁸ The continuing deferrals in many countries reflect institutional inertia and precaution rather than active evidence of danger.

A third common assumption is that all donation centers follow the same rules. They do not. Even within the United States, the American Red Cross, community blood banks, and commercial plasma centers each set their own eligibility criteria within the framework of FDA regulations. Two centers in the same city might give you different answers about your eligibility. If one center turns you away, it is worth calling another and asking about their specific policy for your cancer type and treatment history.

When a Post-Donation Cancer Diagnosis Happens

Sometimes a donor is diagnosed with cancer shortly after giving blood or plasma, raising the question of what happens to the products they donated. Blood centers handle these situations through a process sometimes called “post-donation information” or look-back investigations. The approach varies widely: some centers quarantine or discard unused products from that donor, while others assess the risk based on the type of cancer diagnosed and decide case by case.

The survey of blood collection centers found that responses to post-donation cancer reports varied considerably from center to center.¹ Some treated any cancer diagnosis as grounds to recall products, while others distinguished between blood cancers and solid tumors. This inconsistency mirrors the broader pattern: without hard evidence of transmission risk, each institution is essentially making a judgment call about how cautious to be.

From the recipient’s perspective, the Scandinavian data provides strong reassurance. Even among recipients whose donors were subsequently found to have had cancer at the time of donation, there was no detectable increase in cancer risk.² So while post-donation cancer reports trigger administrative responses at blood centers, they have not been associated with harm to recipients in any large study to date.

Paid Plasma Donation and Cancer History

Many people asking about plasma donation after cancer are specifically interested in paid plasma, which operates through commercial plasma centers rather than nonprofit blood banks. These centers, which compensate donors and collect plasma primarily for manufacturing into pharmaceutical products like immunoglobulins and clotting factors, generally follow FDA regulations for source plasma donors. Their eligibility criteria may differ from those at nonprofit blood collection organizations.

Commercial plasma centers tend to be somewhat more standardized in their screening because the plasma they collect is pooled and processed industrially, meaning it goes through fractionation, purification, and pathogen-reduction steps that whole blood does not. These manufacturing processes add layers of safety that make the already negligible theoretical risk of cancer transmission even more remote. However, the screening questionnaire at a commercial center will still ask about cancer history, and the same general pattern applies: solid tumors after treatment completion are more likely to be accepted than blood cancers.

One practical difference is that commercial plasma centers typically allow much more frequent donation than blood banks, sometimes twice per week. For a cancer survivor whose body is still recovering, this frequency could be physically demanding. The protein and fluid losses accumulate faster with frequent donation, and while research shows that healthy donors tolerate intensive plasmapheresis well over the long term, those studies were conducted on donors without recent major illness.⁷ If you are recently post-treatment, starting at the minimum allowed frequency and paying attention to how you feel is a reasonable approach, and your center’s protein checks at each visit provide a built-in safety net.